Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives / Guarneri, Valentina; A., Frassoldati; Giovannelli, Simona; F., Borghi; Conte, Pierfranco. - In: CANCER LETTERS. - ISSN 0304-3835. - STAMPA. - 248:2(2007), pp. 175-185. [10.1016/j.canlet.2006.07.001]
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives
GUARNERI, Valentina;GIOVANNELLI, Simona;CONTE, Pierfranco
2007
Abstract
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
